These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 36755974)

  • 21. TWIST2-mediated chromatin remodeling promotes fusion-negative rhabdomyosarcoma.
    Shah AM; Guo L; Morales MG; Jaichander P; Chen K; Huang H; Cano Hernandez K; Xu L; Bassel-Duby R; Olson EN; Liu N
    Sci Adv; 2023 Apr; 9(17):eade8184. PubMed ID: 37115930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification and targeting of a HES1-YAP1-CDKN1C functional interaction in fusion-negative rhabdomyosarcoma.
    Kovach AR; Oristian KM; Kirsch DG; Bentley RC; Cheng C; Chen X; Chen PH; Chi JA; Linardic CM
    Mol Oncol; 2022 Oct; 16(20):3587-3605. PubMed ID: 36037042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and Characterization of Novel Small-Molecule SMOX Inhibitors.
    Furbish AB; Alford AS; Burger P; Peterson YK; Murray-Stewart T; Casero RA; Woster PM
    Med Sci (Basel); 2022 Aug; 10(3):. PubMed ID: 36135832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Abbou S; Klega K; Tsuji J; Tanhaemami M; Hall D; Barkauskas DA; Krailo MD; Cibulskis C; Nag A; Thorner AR; Pollock S; Imamovic-Tuco A; Shern JF; DuBois SG; Venkatramani R; Hawkins DS; Crompton BD
    J Clin Oncol; 2023 May; 41(13):2382-2393. PubMed ID: 36724417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD73 contributes to the pathogenesis of fusion-negative rhabdomyosarcoma through the purinergic signaling pathway.
    Hernandez KC; Shah AM; Lopez VA; Tagliabracci VS; Chen K; Xu L; Bassel-Duby R; Olson EN; Liu N
    Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2315925121. PubMed ID: 38227654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction in polyamine catabolism leads to spermine-mediated airway epithelial injury and induces asthma features.
    Jain V; Raina S; Gheware AP; Singh R; Rehman R; Negi V; Murray Stewart T; Mabalirajan U; Mishra AK; Casero RA; Agrawal A; Ghosh B
    Allergy; 2018 Oct; 73(10):2033-2045. PubMed ID: 29729200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma.
    Wu JT; Cheuk A; Isanogle K; Robinson C; Zhang X; Ceribelli M; Beck E; Shinn P; Klumpp-Thomas C; Wilson KM; McKnight C; Itkin Z; Sotome H; Hirai H; Calleja E; Wacheck V; Gouker B; Peer CJ; Corvalan N; Milewski D; Kim YY; Figg WD; Edmondson EF; Thomas CJ; Difilippantonio S; Wei JS; Khan J
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spermine oxidase mediates Helicobacter pylori-induced gastric inflammation, DNA damage, and carcinogenic signaling.
    Sierra JC; Piazuelo MB; Luis PB; Barry DP; Allaman MM; Asim M; Sebrell TA; Finley JL; Rose KL; Hill S; Holshouser SL; Casero RA; Cleveland JL; Woster PM; Schey KL; Bimczok D; Schneider C; Gobert AP; Wilson KT
    Oncogene; 2020 May; 39(22):4465-4474. PubMed ID: 32350444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identify potential driver genes for PAX-FOXO1 fusion-negative rhabdomyosarcoma through frequent gene co-expression network mining.
    Zhan X; Liu Y; Jannu AJ; Huang S; Ye B; Wei W; Pandya PH; Ye X; Pollok KE; Renbarger JL; Huang K; Zhang J
    Front Oncol; 2023; 13():1080989. PubMed ID: 36793601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the future.
    Morel VJ; Rössler J; Bernasconi M
    Med Res Rev; 2024 Nov; 44(6):2730-2773. PubMed ID: 38885148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells.
    De Salvo M; Raimondi L; Vella S; Adesso L; Ciarapica R; Verginelli F; Pannuti A; Citti A; Boldrini R; Milano GM; Cacchione A; Ferrari A; Collini P; Rosolen A; Bisogno G; Alaggio R; Inserra A; Locatelli M; Stifani S; Screpanti I; Miele L; Locatelli F; Rota R
    PLoS One; 2014; 9(5):e96238. PubMed ID: 24797362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.
    Hebron KE; Wan X; Roth JS; Liewehr DJ; Sealover NE; Frye WJE; Kim A; Stauffer S; Perkins OL; Sun W; Isanogle KA; Robinson CM; James A; Awasthi P; Shankarappa P; Luo X; Lei H; Butcher D; Smith R; Edmondson EF; Chen JQ; Kedei N; Peer CJ; Shern JF; Figg WD; Chen L; Hall MD; Difilippantonio S; Barr FG; Kortum RL; Robey RW; Vaseva AV; Khan J; Yohe ME
    Clin Cancer Res; 2023 Jan; 29(2):472-487. PubMed ID: 36322002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KDM3A/Ets1/MCAM axis promotes growth and metastatic properties in Rhabdomyosarcoma.
    Sobral LM; Sechler M; Parrish JK; McCann TS; Jones KL; Black JC; Jedlicka P
    Genes Cancer; 2020; 11(1-2):53-65. PubMed ID: 32577157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNMT3A and DNMT3B Targeting as an Effective Radiosensitizing Strategy in Embryonal Rhabdomyosarcoma.
    Camero S; Vitali G; Pontecorvi P; Ceccarelli S; Anastasiadou E; Cicchetti F; Flex E; Pomella S; Cassandri M; Rota R; Marampon F; Marchese C; Schiavetti A; Megiorni F
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spermine oxidase is upregulated and promotes tumor growth in hepatocellular carcinoma.
    Hu T; Sun D; Zhang J; Xue R; Janssen HLA; Tang W; Dong L
    Hepatol Res; 2018 Nov; 48(12):967-977. PubMed ID: 29923661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of Chromosome 3q Is a Prognostic Marker in Fusion-Negative Rhabdomyosarcoma.
    Dehner CA; Bell RC; Cao Y; He K; Chrisinger JSA; Armstrong AE; Yohe M; Shern J; Hirbe AC
    JCO Precis Oncol; 2023 Sep; 7():e2300037. PubMed ID: 37738543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
    Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
    Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma.
    Zibat A; Missiaglia E; Rosenberger A; Pritchard-Jones K; Shipley J; Hahn H; Fulda S
    Oncogene; 2010 Dec; 29(48):6323-30. PubMed ID: 20818440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The potential of a novel polyamine transport inhibitor in cancer chemotherapy.
    Aziz SM; Gillespie MN; Crooks PA; Tofiq SF; Tsuboi CP; Olson JW; Gosland MP
    J Pharmacol Exp Ther; 1996 Jul; 278(1):185-92. PubMed ID: 8764350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm FGFR4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma.
    Timpanaro A; Piccand C; Uldry AC; Bode PK; Dzhumashev D; Sala R; Heller M; Rössler J; Bernasconi M
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.